Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.34 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276140 | 0.77 | CHRM5 (0.39) | NPC1RAB9AFAAHCES2 | |
| SCHEMBL3853565 | 0.76 | CYP2C9 (0.47) | NPC1RAB9A | |
| SCHEMBL3851051 | 0.71 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL3853970 | 0.70 | NPC1 (0.40) | NPC1RAB9A | |
| SCHEMBL3927571 | 0.69 | HCRTR1 (0.35) | — | |
| SCHEMBL3858424 | 0.69 | KDM4A (0.30) | — | |
| SCHEMBL3853982 | 0.67 | RAB9A (0.42) | NPC1RAB9A | |
| SCHEMBL3924125 | 0.67 | RET (0.32) | — | |
| SCHEMBL3929469 | 0.67 | HCRTR1 (0.32) | NPC1RAB9A | |
| SCHEMBL4919930 | 0.66 | CYP2A6 (0.50) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869032-B8 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| EP-1869032-B1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| EP-1869032-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | NPC1 2756/4885RAB9A 3435/4885FAAH 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.